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The purpose of this research was to develop a topical microsphere delivery system in a thermosensitive 20% poloxamer 407 gel
(Pluronic F127) to control release of KSL-W, a cationic antimicrobial decapeptide, for a period of 4–7 days for potential application
in combat related injuries. KSL-W loaded microsphere formulations were prepared by a solvent extraction-evaporation method
(water-oil-water), with poly (D,L-lactic-co-glycolic acid) (PLGA) (50 : 50, low-weight, and hydrophilic end) as the polymeric
system. After optimization of the process, three formulations (A, B, and C) were prepared with different organic to water ratio of the
primary emulsion while maintaining other components andmanufacturing parameters constant. Formulations were characterized
for surfacemorphology, porous nature, drug loading, in vitro drug release, and antimicrobial activity.Microspheres containing 20%
peptide with porous surfaces and internal structure were prepared in satisfactory yields and in sizes varying from 25 to 50𝜇m. Gels
of 20% Pluronic F127, which were liquid at or below 24.6∘C and formed transparent films at body temperature, were used as carriers
for the microspheres. Rheological studies showed a gelation temperature of 24.6∘C for the 20% Pluronic F127 gel alone. Gelation
temperature and viscosity of formulations A, B, and C as a function of temperature were very close to those of the carrier. A Franz
diffusion cell system was used to study the release of peptide from the microspheres suspended in both, phosphate-buffered saline
(PBS) and a 20% Pluronic F127 gel. In vitro release of greater than 50% peptide was found in all formulations in both PBS and the
gel, and in one formulation there was a release of 75% in both PBS and the gel. Fractions collected from the release process were
also tested for bactericidal activity against Staphylococcus epidermidis using the broth microdilution method and found to provide
effective antimicrobial activity to warrant consideration and testing in animal wound models for treating combat-related injuries.
1. Introduction
Combat-related injuries duringmilitary operations have been
associated with infectious complications due to the nature of
wounding, giving rise to significant devitalized tissue, con-
tamination of battlefield wounding agents with various bac-
teria, and the emergence of multidrug-resistant nosocomial
pathogens, especially gram-negative bacteria. Investigations
are underway to identify the source of these bacteria and
to try to mitigate their associated morbidity and mortality.
As in the US civilian medical community, new antimicrobial
agents are needed to treat these infections. Platforms to
identify infection and its antimicrobial resistance profile also
are needed to ensure that appropriately focused therapy is
instituted [1].
Cationic antimicrobial peptides are excellent candidates
for development as novel therapeutic agents to comple-
ment conventional antibiotic therapy [2]. In contrast to
conventional antibiotics, antimicrobial peptides have lower
propensity to induce antibiotic resistance. These peptides
generally exhibit a broad range of bactericidal activity which
requires a short contact time to induce killing. However,
many available peptide and protein drugs are characterized
by short biological half-lives. They are easily degraded by
enzymes and pass poorly through biological barriers because
of deficient diffusivity and low partition coefficient [3–6].
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The assessment of protein stability in delivery systems is
increasingly being integrated into research programs. Among
the various means used, nanospheres or microspheres made
of poly (D,L-lactic-co-glycolic acid) (PLGA) have gained
popularity, mainly because of their tissue compatibility and
biodegradability [7]. Poly (lactic-co-glycolic acid) (PLGA)
is made from two monomers, lactic acid and glycolic acid.
The ratio of the monomers and the molecular weight set
the identity and properties. PLGA is both biodegradable and
biocompatible, and since both monomers occur naturally
it has minimal toxicity. PLGA is naturally amorphous (not
crystalline). While poly (lactic) and poly (glycolic) acid
are poorly soluble in most solvents; PLGA dissolves in
many common solvents including tetrahydrofuran, acetone,
ethyl acetate, and chlorinated solvents. The Food and Drug
Administration (FDA) has approved PLGA for preparation
of micro- and nanoparticles.
Peptide encapsulation and preparation of PLGA micro-
spheres are generally performed using a water-in-oil-in-
water double-emulsion technique. In this process, the active
ingredient is first dissolved in an aqueous phase (W), which
is then emulsified in an organic solvent (O) of a polymer to
make a primary W/O emulsion. This primary emulsion is
further mixed in an emulsifier-containing aqueous solution
(W) to make a W/O/W double emulsion. The removal of
the polymer solvent leaves microspheres in the aqueous
continuous phase, making it possible to collect them by fil-
tering or centrifuging [8–10]. Incorporating the drug-loaded
microspheres into a thermoreversible gel would provide
a novel platform in the treatment of persistent infections
arising from localized biofilms [11–13].
Microspheres with high peptide incorporation efficiency
can be prepared from low molecular weight and hydrophilic
acid ended PLGA polymers [14]. As a vehicle or carrier,
Pluronic F-127, in concentrated solutions (>18% in water),
can be transformed from low-viscosity transparent solutions
to solid gels on warming to body temperature [15, 16].
This phenomenon, therefore, suggests that when poured
or sprayed onto the skin, the gel preparation will form a
semisolid artificial barrier and a sustained release depot.
Pluronic F-127 consist of ethylene oxide (EO) and
propylene oxide (PO) blocks arranged in a triblock struc-
ture (EO)
𝑥
-(PO)
𝑦
-(EO)
𝑥
; the chemical formula is HO[CH-
CH
2
O]
𝑥
[CH(CH
3
CH
2
O)]
𝑦
where x = 95–105 and y = 54–
60. It has a molecular weight of about 12,600 (9,840–14,600).
The gelation mechanism of pluronic solutions indicates a
micellar mode of association. Micelle formation occurs at the
critical micellization temperature as a result of polypropylene
oxide block dehydration.With the increasing of temperature,
micellization becomes more important and, at a certain
temperature, micelles come into contact and no longer move.
This packing of micelles and micelle entanglement might be
the possible mechanism of pluronic solution gelation with
increase of temperature.
The purpose of the present work was to develop a
thermosensitive gel loaded with biodegradable microspheres
that release an antimicrobial peptide up to one week.
The microspheres were manufactured using a water-in-oil-
in-water double-emulsion solvent evaporation technique.
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Figure 1: High-performance liquid chromatogram of KSL-W
(0.5mg/mL) in DI water.
By monitoring the organic to water ratio of the primary
emulsion while maintaining constant other manufacturing
parameters, desired porosity of microspheres that fill the
pharmacokinetic requirements may be achieved [17].
2. Materials and Methods
KSL-W (sequence KKVVFWVKFK-CONH2), lot no.
05US1311-B, MW 1307, was custom synthesized by Synprep
(Dublin, CA); PLGA 502H (poly (D,L-Lactide-co-glycolide
50 : 50 MW 11,300, lot no. STBB9327V); pharmaceutical
grade polyvinyl alcohol low-viscosity, lot no. MKBD9933V,
MW: 31,000–50,000, 98%-99% hydrolyzed were obtained
from Sigma; Lutrol F127 (Pluronic F127), lot no. WPTF531B,
was provided by Q.BASF; Mueller Hinton broth (Becton,
Dickinson and Company, Spark, MD). All other chemicals
used were analytical grade and were obtained from Sigma.
2.1. KSL-WAssay. KSL-Wcontent ofmicrosphereswas deter-
mined by reverse-phase high-performance liquid chromatog-
raphy (HPLC) using aWaters 600 Emultisolvent delivery sys-
tem consisting of aWaters 600 pump and controller, aWaters
717 plus autosampler, and a Waters 996 photodiode array
detector. The column used was a Prosphere C18-300 (4.6 ×
250mm, 5 𝜇m). A gradient elusion was accomplished with
acetonitrile : water : trifluoroacetic acid 10% : 90% : 0.1% (A)
and acetonitrile : water : trifluoroacetic acid 70% : 30% : 0.1%
(B) and increasing the amount of B from 0 to 100% over 20
minutes at a flow rate of 1.0mL/min. Each sample was run
for 35min with a 5min lag time between samples. KSL-W
shows a peak at a retention time of 14.245min (Figure 1).
Standard curves of KSL-W ranging from 6.25 𝜇g/mL to
1mg/mL yielded linear responses over the concentration
range with detection at 280 nm (Figure 2(a)). KSL-W release
from microspheres incorporated in the gel was determined
by UV spectrophotometry at 280 nm using an Eppendorf
Biophotometer (Figure 2(b)).
2.2. Preparation of Microspheres. PLGAmicrospheres loaded
with KSL-W were prepared by using the double-emulsi-
fication solvent evaporation method (W/O/W) [18–20], with
PLGA 50 : 50, low-weight, and hydrophilic end, as the poly-
meric system.Three formulations having different organic to
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Figure 2: KSL-W standard curves (280 nm). (a) high-performance liquid chromatography; (b) UV spectrophotometry. Readings were
obtained from samples determined in triplicates (mean ± standard errors).
water ratio of the primary emulsion were prepared. Other
conditions and variables applied for the preparation of KSL-
W microspheres were maintained constant. Formulations
composition is shown in Table 1.
KSL-W was dissolved in deionized water and Tween 20
was added. The PLGA was dissolved in dichloromethane
(CH
2
Cl
2
). The KSL-W solution was slowly added to the
PLGA solution to form a primary W/O emulsion by stir-
ring with an Ultraturrax homogenizer at 24,000 rpm for
5 minutes. The primary emulsion was slowly poured into
200mL of 10× phosphate-buffered saline (10×-PBS), pH 7.4
containing 0.20 or 0.35%polyvinyl alcohol (PVA), and stirred
at 1,800 rpm (overhead propeller) for sufficient time to form
microspheres. This allowed the CH
2
Cl
2
to evaporate prior
to filtration and rinsing. Figure 3 depicts this evaporation
method for preparing microspheres. Following filtration and
rinsing, the solidified microspheres were transferred from
the filter to centrifuge tubes, washed three times with DIW,
centrifuged at 2,500 rpm for 10min, and dried at 25∘C under
vacuum overnight.
2.3. Characterization of KSL-W/PLGA Microspheres. The
characterization focused on comparing the porosity of the
microspheres produced, and correlating such porosity to the
in vitro release profiles of the final formulations. Determining
how this porosity affected other MS parameters (surface
morphology, particle size, drug content, loading efficiency
%, Yield %) allowed a selection of the formulation(s) that
guaranteed bactericidal activity of the delivery system for
at least one week. The antimicrobial activity of the release
fractions collected for each KSL-Wmicrosphere formulation
was determined against Staphylococcus epidermidis.
2.3.1. Microsphere Surface Morphology and Particle Size.
Scanning electron microscopy (SEM) (Zeiss Field Emission,
Sigma VP-40, Germany) was used to characterize the surface
morphology of microspheres. Microspheres were mounted
directly on the SEM stub using double stick carbon tape,
coated with gold/palladium, and scanned in a high-vacuum
chamber with a focused electron beam. Secondary electrons
emitted from the sample were detected and the image was
formed. The average particle size and size distribution were
determined by using Smart Tiff from Zeiss.
2.3.2. Drug Content (KSL-W Content in the Microsphere Pow-
der) (See [21]). Fiftymg of peptide loadedmicrospheres were
quantitatively weighed and dissolved in 2mL of CH
2
CL
2
, and
the peptide was extracted with 10mL of 0.1M acetate buffer
with a pHof 4.0 by shaking for 1 hour in awrist-action shaker.
The aqueous buffer phase was separated by centrifugation,
and the extracted peptide concentration was determined by
reversed-phase HPLC
KSL-W in MS powder (% w/w)
= [Cb (mg/mL) × 10mL
50mg
] × 100
Cb = KSL-W concentration in acetate buffer (mg/mL) .
(1)
2.3.3. Loading Efficiency (%)
Loading efficiency (%)
=
(total amount of KSL-W in microspheres) × 100
Amount of KSL-W initially weighed
.
(2)
2.3.4. Yield (%). Obtained microspheres were weighed, and
percentage yield was determined by using the following
formula:
Yield (%)
= (
weight of MS obtained
total weight of KSL-W and PLGA used
) × 100.
(3)
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primary
emulsion
Ultraturrax
24,000 rpm
PLGA CH2Cl2
PLGA/CH2Cl2KSL-W
solution
Water bath
25–40∘C
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Figure 3: Schematic of the double-emulsification solvent extraction/evaporationmethod for the preparation of KSL-W-PLGAmicrospheres.
Polycarbonate (PC) membrane filter (1 𝜇m size cutoff) was used to filter the MS.
2.4. Preparation and Rheological Tests of
Thermosensitive Formulations
2.4.1. Preparation of Concentrated Pluronic (F127) Solution
(See [22]). Aqueous 22.2% pluronic F127 w/v was prepared
by the cold method described by Schmolka [22].Themethod
involved slow addition of polymer in cold water with contin-
uous agitation. The mixture was stored overnight at 4∘C to
obtain a clear solution.
2.4.2. Incorporation of MS in Pluronic (F127) Solution. Dried
microspheres were resuspended in 2mL distilled water. This
suspension was added to the cold concentrated pluronic
(F127) gel so that the final concentration of pluronic reached
20% w/v and gently stirred for 10min for uniform distribu-
tion of MS in the pluronic.
2.4.3. Gelation Temperature (Tg) Measurement (See [23]).
Ten mL of cold formulation and a magnetic stir bar were
placed into a 25mL glass vial that had been placed in a
low-temperature water bath. A thermometer probe was im-
mersed into the sample solution.The temperature was slowly
increased (2∘C/min) under continuous stirring. Temperature
at which the magnetic bar stopped moving was reported as
the gelation temperature (Tg).
2.4.4. Viscosity Measurement (Centipoises, cP). Formulation
viscosities were measured using a low viscosity Brookfield
viscometer (model LVDV-E-115, Cole Palmer, Vernon Hills,
IL, USA) with a small sample volume adapter and spindles
no. 61 (for low viscosity) and no. 34 (for higher viscosity).
Viscosity of formulations was measured at seven different
temperatures. These included the gelation temperature (Tg),
BioMed Research International 5
Table 1: KSL-W/PLGA microspheres: composition of formulations and manufacturing parameters.
Formulation PLGA(mg)
(CH2Cl2)
(mL)
KSL-W
(mg)
KSL-W
Solvent
PVA %
(w/v)
Stirring
(∘C) Time
A 600 20 200 2mL DIW
∗
0.1mL Tween 20 0.35
25∘C 30m
40∘C 1 hr
B 600 20 200 4mL DIW + 0.1mL Tween 20 0.35 25
∘C 30m
40∘C 1 hr
C 600 20 200 3mL DIW + 0.1mL Tween 20 0.35 25
∘C 30m
40∘C 1 hr
∗DIW: deionized water.
four temperatures below the Tg, and two temperatures above
the Tg. The principle of operation of the DV-E viscometers
is to rotate a spindle (immersed in the test fluid) through a
calibrated spring. The viscous drag of the fluid against the
spindle is measured by the spring deflection in centipoises
(cP) or millipascal seconds (mPa⋅s). 1 cP = 1mPa⋅s.
2.5. In Vitro Release Profile and Bactericidal Activity of
Final Formulations
2.5.1. In Vitro Release Profile (See [24–26]). In vitro release
profile of KSL-W from the PLGAmicrospheres suspended in
PBS and in 20% Pluronic F127 gel was performed in triplicate
for each formulation using a six-station Franz diffusion cell.
A half of a mL of each microsphere suspension was placed
into each corresponding donor chamber of the instrument.
Thedonor chamberwas separated from the acceptor chamber
by a 0.1-𝜇m polycarbonate (PC) membrane. The medium
solution in the acceptor chamber was 5mL PBS at pH 7.4.
Acceptor chamber was kept at 37∘C (circulating water) and
was continuously stirred (magnetic stirrer). Release samples
of 0.2mL were removed at different intervals (1, 2, 4, 6, and
12 hours and 1 to 7 days) from the acceptor chamber. The
volume of the sample removed was replaced with the same
volume of fresh buffer after each sampling. KSL-W content
was evaluated by a UV-Vis spectrophotometer at 280 nm, and
the amount of KSL-W was determined by extrapolation in a
previously prepared calibration curve.
2.5.2. Bactericidal Activity (See [27]). Bactericidal activity
was determined against Staphylococcus epidermidis using
the broth microdilution method. Freshly grown cultures of
Staphylococcus epidermidis at exponential phase were used
as the inoculum. Bacteria were centrifuged at 4,000 rpm for
15min at 4∘C, suspended in 2× Mueller Hinton broth, and
adjusted to approximately 4 × 106 colony-forming units (cfu)
per milliliter in 2× Mueller Hinton broth. Release sample
(100 𝜇L) was added to each well of a 96-well, flat-bottomed
plate (Becton Dickinson, Spark, MD, USA). The solution
was serially diluted (twofold) with sterile distilled water in
the wells. Aqueous KSL-W peptide at 200𝜇g per mL, which
served as the positive control, was included in the assay and
serially diluted in sterile distilled water as the release sample.
After dispensing 100-𝜇L aliquots of bacterial suspension into
the wells, the 96-well plates were incubated at 37∘C for 24
hours. The minimum inhibitory concentration (MIC) was
defined as the lowest concentration of the release sample
(containing released peptide) or KSL-Wpeptide solution that
prevented visible turbidity, asmeasured at 600 nmbyusing an
ELISA reader (BIOTEK, Winooski, VT, USA).
3. Results and Discussion
Table 1 shows that differences in composition of formulations
A, B, and C are only in the amount of water used to dissolve
the peptide in the O/W primary emulsion. Other variables
and manufacturing parameters have remained constant;
therefore, we can assume that differences in properties of the
obtained MS are due to differences in the organic to water
(O/W) ratio of their initial composition.
The scanning electron micrographs (SEMs) are shown in
Figures 4, 5, and 6. The microparticles were spherical for the
three formulations and essentially free of aggregation. Surface
morphology showed smooth surfaces with varying porosity
from low for Formulation A to high for B and C, with C
being the highest. Fractured particles of A and B reveal a very
porous interior.
The properties and characteristics of the peptide-loaded
PLGA microspheres are tabulated in Table 2. Yields ranged
from 68 to 84% with loading efficiencies of 68–78% and drug
contents of 17–20%. The average particle size as determined
from the SEMs was 46.42 𝜇m ± 17.9 𝜇m for Formulation A
(Figure 7(a)), 25.8𝜇m ± 14.1 𝜇m for 02–15 (Figure 7(b)) and
40 𝜇m ± 12.8 𝜇m for C (Figure 7(c)). Surface area measure-
ments were not performed but formulation A, due to larger
particle size, would have the lowest surface area, while C
would have a higher surface area than A but lower than B
which has the smallest particle size.
In vitro release of KSL-W from the microspheres sus-
pended in PBS and in 20% Pluronic 127 is listed in Table 2 at
150 hours for comparative purposes, since a delivery system
lasting 4 to 7 days in a wound is necessary. As shown
in Figure 8, more than 60% was released in 150 hours for
the three formulations with B showing the highest release,
74.8% in PBS and 76.3% in the gel. There is no detectable
burst release difference of MS formulations in Pluronic F127
20% gel. But the release for A decreased considerably after
96 hours in this medium. The subsequent slower rate is
understandable considering the larger particle size and lower
porosity for A, giving rise to lower specific surface area and a
resulting lower polymer degradation rate.
Release of the peptide from the microsphere is con-
trolled by two mechanisms: diffusion of the protein out of
6 BioMed Research International
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Figure 4: SEM images of microsphere Formulation A.
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Figure 5: SEM images of microsphere Formulation B.
Table 2: KSL-Wmicrosphere properties.
Formulation Surfacemorphology Yield (%) KSL-W content (%)
Loading efficiency
(%)
average size (𝜇m)
𝑛 = 30
% Release at 150 hours
In PBS In Gel
A
Spherical,
high surface
porosity
75 17 68 46.4 ± 17.9 52.0 ± 2.5 64.4 ± 2.7
B
Spherical,
high surface
porosity
84 19 77 25.8 ± 14.1 74.8 ± 2.3 76.3 ± 1.2
C
Spherical,
high surface
porosity
68 20 78 40.0 ± 12.8 53.3 ± 4.5 68.3 ± 3.6
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Figure 6: SEM images of microsphere Formulation C.
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Figure 7: KSL-W PLGA microspheres particle size and particle size distribution using Smart Tiff from Zeiss; 𝑛 = 30. Average means;
Formulation A, 46.4 𝜇m ± 17.9𝜇m; Formulation B, 25.8 𝜇m ± 14.1 𝜇m; Formulation C, 40.0 𝜇m ± 12.8 𝜇m.
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Figure 8: In vitro peptide release test utilizing the Franz diffusion cell. Formulation A (󳵳); Formulation B (◼); and Formulation C (Q). In
all samples, 𝑛 = 3. Membrane filter: 0.1 𝜇m PC. Acceptor media: 5mL PBS pH 7.4. Sampling volume: 0.2mL. Sample size in donor chamber:
0.5mL.
themicrosphere and erosion of the polymermatrix. Typically,
the diffusion process consists of an initial “burst” release of
peptide at or near the surface of the microsphere followed
by the additional release of protein from the pores of the
microsphere. Erosion occurs by hydrolysis of the polymer
matrix generating pores that expose interior pockets of
peptide to the bathing liquid. For continuous release, the
diffusion and erosion process must balance each other to
allow the peptide to diffuse out of the microsphere at a
constant rate.
The formulations produced in this study did not yield a
complete release of the peptide. A number of reasons could
cause the incomplete release when double-emulsion/solvent
evaporation method is being used as in this study. For
example, one of the possible causes for the incomplete release
observed might be due to nonspecific adsorption of peptides
to interfaces or to microsphere materials. In addition, the
peptide could potentially be denatured or degraded when
exposed to a variety of stress conditions including heat, shear,
and organic solvents exposure during the preparation of
microspheres.
Even though not very high in our case, in general,
hydrophilic polymers in the formulations result in a high
initial burst and high release rates when PLGAwith relatively
high glycolide content (50/50) is used [28]. The higher
glycolide content makes the polymer more hydrophilic and
facilitates water uptake from the release medium. The PLGA
used in the formulations (D,L-Lactide-glycolide 50 : 50, acid
terminated, MW 7,000 to 17000 from Sigma) corresponds
to Resomer RG 502H, a PLGA carrying free carboxylic end
groups that resulted in a higher incorporation efficiency, as
well as a higher hydration, as compared to the end-capped
polymer [29].
Release from both B and C microsphere formulations
was continuous with B showing a similar release profile in
both PBS and the Pluronic gel. What is difficult to explain
is the similar release for B in PBS and in the gel, while for C
release was greater in the gel. Evidently, hydration in the gel
may be greater or the pluronic may accelerate the polymer
degradation. Nevertheless, a release of 75% at 150 hours from
the Bmicrospheres in both PBS and the Pluronic gel suggests
that this is the preferable formulation to pursue as a wound-
healing device.
Table 3 and Figure 9 show that the gelation temperature
and viscosity of formulations A, B, and C were very close to
those of the blank formulation (pluronic F127 20% solution
containing no MS powder) suggesting that MS powder did
not interfere with the rheological properties of the carrier.
Ideally an in situ gelling system used in an open wound or
burned skin should be low in viscosity as a free flowing liquid
to allow for easy and accurate topical administration to the
injured site.The gel formed following phase transition at body
temperature should be strong enough to remain on the site
and exhibits a long residence time. This provides a platform
for a continued and sustained release of the loaded drug to
enhance bioavailability, reduce systemic absorption, and the
need for frequent administration leading to improved patient
compliance [30]. The formulations reported in this study
possess some of these properties. However, future efforts will
be to increase the gelation temperature of the formulations to
broaden their application to meet various extreme ambient
temperatures.
Antimicrobial activity of the release fraction collected
for each KSL-W microsphere formulation as determined
against staphylococcus epidermidis using the broth microdi-
lution method is shown in Figure 10. After proper dilution
of each collected fraction for the starting concentration in
the bactericidal assay, all three microsphere formulations
(Formulations A, B, and C) tested showed antimicrobial
activity (MIC around 6.25𝜇g/mL). S. epidermidis, one of the
most prevalent bacteria found on human skin and mucous
membrane microbial flora, has emerged as major source of
nosocomial infections of implanted devices.These coagulase-
negative staphylococci readily form biofilms on surfaces.
4. Summary and Conclusion
Utilizing a thermosensitive gel, the sustained release of
an antimicrobial peptide, KSL-W, in porous, hydrophilic,
BioMed Research International 9
10
100
1000
10000
100000
1000000
10 15 20 25 30 35 40
Vi
sc
os
ity
 (c
p)
Viscosity versus temperature
Pluronic F127 20%
Formulation A
Formulation B
Formulation C
Temperature (∘C)
Figure 9: Viscosity profiles of formulations prepared from pluronic F127 as a function of temperature. Formulation A (󳵳); Formulation B
(◼); and Formulation C (Q); Pluronic F127 20% Blank (∙). All test formulations and the blank carrier display similar viscosity profiles as a
function of the temperature. Readings (mean ± standard deviations) are from samples tested in triplicates.
0
5
10
15
20
25
0
200
400
600
0 50 100 150
Time (hrs)
Formulation A
Activity (MIC 𝜇g/mL)
Release of KSL-W (𝜇g/mL)
Ac
tiv
ity
 (M
IC
𝜇
g/
m
L)
Re
le
as
e o
f K
SL
-W
 (𝜇
g/
m
L)
(a)
0
5
10
15
20
25
0
200
400
600
0 50 100 150
Time (hrs)
Formulation B
Activity (MIC 𝜇g/mL)
Release of KSL-W (𝜇g/mL)
Ac
tiv
ity
 (M
IC
𝜇
g/
m
L)
Re
le
as
e o
f K
SL
-W
 (𝜇
g/
m
L)
(b)
0
5
10
15
20
25
0
200
400
600
0 50 100 150
Formulation C
Time (hrs)
Activity (MIC 𝜇g/mL)
Release of KSL-W (𝜇g/mL)
Ac
tiv
ity
 (M
IC
𝜇
g/
m
L)
Re
le
as
e o
f K
SL
-W
 (𝜇
g/
m
L)
(c)
Figure 10: Bactericidal activity of fractions collected from KSL-W PLGA microsphere formulation release using the broth microdilution
method. The MIC of KSL-W peptide alone against S. epidermidis was 6.25 𝜇g/mL.
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Table 3: Gelation temperature (Tg), viscosity, and pH of Formulations.
Formulation
code
Gelation temp.
(Tg): ∘C
Viscosity (cp) pH
10∘C 15∘C 20∘C 24.6∘C 25∘C 37∘C
Blank∗C 24.6 ± 0.1 39.2 ± 1.5 38.2 ± 0.2 75.0 ± 2.5 103,820.0 ± 16.2 120,216.7 ± 46.4 195,616.7 ± 224.8 6.6 ± 0.2
AC 24.7 ± 0.2 40.5 ± 0.2 36.2 ± 0.2 111.0 ± 2.9 117,426.7 ± 90.0 121,533.3 ± 205.5 196,133.3 ± 249.4 6.5 ± 0.1
BC 24.6 ± 0.1 41.0 ± 0.5 37.1 ± 0.2 130.0 ± 13.0 110,400.0 ± 294.3 118,485.3 ± 283.8 196,500.0 ± 294.4 6.4 ± 0.2
CC 24.7 ± 0.1 34.5 ± 0.6 38.3 ± 0.4 122.7 ± 3.9 122,400.0 ± 374.2 124,216.7 ± 201.4 195,666.7 ± 0.4 6.7 ± 0.1
∗Pluronic F127 20% solution.
CReadings represent the average (±standard deviations) of samples in triplicates.
low molecular weight polylactide-co-glycolide microspheres
provided antimicrobial activity for up to one week. All three
formulations produced showed a similar gelation profile as
compared to that of the carrier. Fractions collected from
the in vitro release media of the three formulations studied
showed antimicrobial activity against the targeted microor-
ganism Staphylococcus epidermidis. These results suggest
that a KSL-W microsphere in 20% Pluronic F127 gel has
considerable potential as a delivery system for achieving
antimicrobial activity and effective wound healing in combat-
related injuries. Formulation B was selected as the choice for
further characterization based on the total percent release
(Figure 8) which is higher than formulations A & C. In
addition, formulation B possesses the smallest particle size
among all three formulations (Figure 7).
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